The Mechanism and Therapeutic Progress of Heart Failure after Myocardial Infarction

心血管疾病(CVD)是全球最常见的死亡和发病原因，急性心肌梗死(AMI)通常是心血管疾病的首发临床表现，对患者的生存和生活质量造成了极其严重的影响。随着经皮冠状动脉介入治疗(PCI)技术的不断普及，AMI患者的住院死亡率显著降低。然而，AMI所致心力衰竭(HF)的发病率却持续上升，伴随而来的是死亡风险的显著增加。本综述系统探讨了心肌梗死后心力衰竭的发病机制及当前药物治疗的前沿进展。Cardiovascular disease (CVD) is the most common cause of death and morbidity worldwide. Acute myocardial infarction (AMI) is usually the first clinical manifestation of CVD, which has an extremely serious impact on the survival and quality of life of patients. With the continuous popularization of percutaneous coronary intervention (PCI) technology, the in-hospital mortality rate of AMI patients has significantly decreased. However, the incidence of heart failure (HF) caused by AMI has continued to rise, accompanied by a significant increase in the risk of death. This review systematically explores the pathogenesis of heart failure after myocardial infarction and the cutting-edge progress of current drug treatment.